SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137Takayuki Kamikawa, Tomoyuki Igawa|Journal for ImmunoTherapy of Cancer|2024Cited by 13